MNPR

MNPR

USD

Monopar Therapeutics Inc. Common Stock

$82.710-3.240 (-3.770%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$85.950

उच्च

$86.140

कम

$80.105

मात्रा

0.14M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

510.3M

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

0.07M

एक्सचेंज

NCM

मुद्रा

USD

52-सप्ताह रेंज

कम $14.877वर्तमान $82.710उच्च $105

संबंधित समाचार

Analyst Upgrades

Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics with a Overweight rating and announces Price Target of $125.

और देखें
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Analyst Upgrades

Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142

Raymond James analyst Chris Raymond maintains Monopar Therapeutics with a Strong Buy and raises the price target from $80 to $142.

और देखें
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics with a Buy and raises the price target from $70 to $105.

और देखें
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
Analyst Upgrades

Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics with a Overweight and raises the price target from $76 to $95.

और देखें
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
Analyst Upgrades

Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics with a Buy and raises the price target from $60 to $85.

और देखें
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
Analyst Upgrades

BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics with a Buy and raises the price target from $87 to $104.

GlobeNewswire

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics", "Monopar", or the "Company"), a clinical-stage biopharmaceutical company developing innovative

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।